Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Completed Phase 1 Interventional Results available

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

NCT04370873
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 26, 2026, 2:37 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

NCT05644769
View directory record Official record
Conditions
Hypertension
Interventions
Determine the presence of Human sequence Ang-(1-12) on no medication, Human sequence Ang-(1-12) on Lisinopril 40mg every day
Other · Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome

NCT01363141
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Regular AGE Diet, Low AGE Diet
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP)

NCT05852054
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Hypertension in Pregnancy, Dysglycemia
Interventions
OB Provider Clinical Decision Support (CDS), Patient Education (OB Visit), Text messaging, Patient Outreach, Primary Care Provider Clinical Decision Support (CDS), Patient Education (Primary Care Visit)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
2,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 26, 2026, 2:37 PM EDT
Terminated No phase listed Observational

Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study

NCT04090866
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right-Sided Heart Failure
Interventions
PET/MRI
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 26, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video Observations

NCT00522600
View directory record Official record
Conditions
Glaucoma, Dry Eye Syndrome, Conjunctivitis
Interventions
Not listed
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions
PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 26, 2026, 2:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Probiotic Effect on Dietary Nitrate to Plasma Nitrite Production ( OPEDNPN )

NCT06375694
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Diabetes
Interventions
Herbiotics Oral + Ent Probiotic, Placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 26, 2026, 2:37 PM EDT
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PDE5 inhibitor, Endothelin Receptor Antagonists
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
13,021 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 26, 2026, 2:37 PM EDT
Completed No phase listed Observational

Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure

NCT03418753
View directory record Official record
Conditions
Intracranial Pressure Increase
Interventions
EyeBOX for ICP
Diagnostic Test
Lead sponsor
Oculogica, Inc.
Industry
Eligibility
4 Years to 70 Years
Enrollment
60 participants
Timeline
2018 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 26, 2026, 2:37 PM EDT
Withdrawn Phase 3 Interventional

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, iNO
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.

NCT00386607
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 4 Interventional

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

NCT00058929
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients

NCT00734630
View directory record Official record
Conditions
Hypertension
Interventions
nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
75
States / cities
Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 26, 2026, 2:37 PM EDT
Terminated Not applicable Interventional

ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients

NCT03121092
View directory record Official record
Conditions
Hypertension, Hypotension
Interventions
ACEI or ARB
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 4 Interventional

Smoking Study With Behavioral Therapy for Hypertensive Patients

NCT00879177
View directory record Official record
Conditions
Cigarette Smoking, Hypertension
Interventions
Varenicline, behavioral therapy
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 26, 2026, 2:37 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

NCT01739400
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg tablet, once daily.
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 3 Interventional

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

NCT00171041
View directory record Official record
Conditions
Hypertension
Interventions
valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 16 Years
Enrollment
265 participants
Timeline
2002 – 2006
U.S. locations
1
States / cities
E.Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 26, 2026, 2:37 PM EDT
Withdrawn Not applicable Interventional

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

NCT02524431
View directory record Official record
Conditions
Glaucoma
Interventions
Collection of trabecular meshwork tissue during surgery
Other
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 26, 2026, 2:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

NCT01942395
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (DASH/SRD), Control Diet
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Phase 2 Interventional

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT00051194
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Combination IOP Lowering Therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 26, 2026, 2:37 PM EDT
Completed Early Phase 1 Interventional Results available

Aqueous Humor Dynamics and Brimonidine

NCT01144494
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Artificial tears
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 26, 2026, 2:37 PM EDT